logo
Plus   Neg
Share
Email

5 Top Losers In Healthcare Sector (EMMA, MBOT, XERS…)

pharmadown-sept10-lt.jpg

The following are some of the healthcare stocks that posted the biggest percentage decline on Tuesday.

1. Emmaus Life Sciences Inc. (EMMA)

Emmaus Life Sciences, formerly known as MYnd Analytics Inc., is a commercial-stage biopharmaceutical company.

Lost 38.31% to close Tuesday's (Sep.10) trading at $2.77.

News: Emmaus common stock and warrants will be delisted from The Nasdaq Stock Market at the start of trading on Wednesday, September 11, 2019.

The Company is not compliant with the $5 million minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1)) as well the 400 minimum Round Lot holder requirement under Nasdaq Listing Rule 5515(a)(1).

2. Protagonist Therapeutics Inc. (PTGX)

Protagonist Therapeutics is a clinical stage biopharmaceutical company.

Lost 38.31% to close Tuesday's trading at $2.77.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase II study of PTG-300, an injectable hepcidin mimetic, in the treatment of patients with transfusion-dependent as well as non-transfusion dependent beta-thalassemia, dubbed TRANSCEND, is underway, with initial results expected in the fourth quarter of 2019, and final topline data expected in the first half of 2020.
-- A phase II study of PTG-300 in polycythemia vera is expected to begin in the third quarter of 2019.
-- A phase II study of PTG-300 in hereditary hemochromatosis and an investigator-sponsored trial PTG-300 in patients with myelodysplastic syndromes are planned for early 2020.
-- A global phase II clinical study of PTG-200 in Crohn's disease is expected to be initiated in the fourth quarter of 2019.
-- A phase II study of PN-943 in patients with ulcerative colitis is expected to be initiated in early 2020.

3. Stoke Therapeutics Inc. (STOK)

Stoke Therapeutics Inc is an early-stage biopharmaceutical company developing antisense oligonucleotide medicines for genetic diseases affecting the central nervous system, eye, liver, and kidney.

Lost 13.98% to close Tuesday's trading at $28.80.

News: No news

Pipeline and Near-term Catalysts:

The lead product candidate is STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy.

-- Initiation of a phase I/II trial of STK-001 in Dravet syndrome is expected in the first half of 2020.
-- Nomination of the second product candidate for the treatment of an additional genetic disease expected by the first half of 2020.

4. Microbot Medical Inc. (MBOT)

Microbot Medical is a medical device company specializing in the design and development of transformational micro-robotic medical technologies.

Lost 13.51% to close Tuesday's trading at $6.40.

News: The Company announced that its Self-Cleaning Shunt for treating Hydrocephalus, also known as "water in the brain", clearly demonstrated the ability to prevent shunt occlusion in a follow-up In-vitro laboratory study. The stock took a hit despite the positive news.

Near-term Catalysts:

-- The results of the pre-clinical studies to further evaluate the safety and efficacy of the Self-Cleaning Shunt being performed at Wayne State University and Washington University School of Medicine in St. Louis, are expected to be reported during the fourth quarter of 2019 and the first quarter of 2020, respectively.

5. Xeris Pharmaceuticals Inc. (XERS)

Xeris is a speciality pharma company developing ready-to-use injectable and infusible drugs, primarily for the treatment of Hypoglycemia or low blood sugar.

Lost 10.97% to close Tuesday's trading at $9.74.

News: The FDA has approved GVOKE (glucagon) injection, the Company's ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.

GVOKE is Xeris' first commercial product.

For comments and feedback contact: editorial@rttnews.com

Follow RTT